Alimera Sciences, Inc. (ALIM)
NASDAQ: ALIM · IEX Real-Time Price · USD
5.52
0.00 (0.00%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Alimera Sciences Revenue
Alimera Sciences had revenue of $90.22M in the twelve months ending March 31, 2024, with 61.75% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $23.01M with 69.87% year-over-year growth. In the year 2023, Alimera Sciences had annual revenue of $80.75M with 49.19% growth.
Revenue (ttm)
$90.22M
Revenue Growth
+61.75%
P/S Ratio
3.21
Revenue / Employee
$585,838
Employees
154
Market Cap
289.18M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 80.75M | 26.63M | 49.19% |
Dec 31, 2022 | 54.13M | -4.90M | -8.30% |
Dec 31, 2021 | 59.03M | 8.21M | 16.15% |
Dec 31, 2020 | 50.82M | -3.12M | -5.79% |
Dec 31, 2019 | 53.94M | 7.34M | 15.76% |
Dec 31, 2018 | 46.60M | 10.69M | 29.76% |
Dec 31, 2017 | 35.91M | 1.58M | 4.60% |
Dec 31, 2016 | 34.33M | 11.90M | 53.01% |
Dec 31, 2015 | 22.44M | 14.02M | 166.39% |
Dec 31, 2014 | 8.42M | 6.55M | 349.95% |
Dec 31, 2013 | 1.87M | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amarin Corporation | 277.46M |
Zynex | 188.68M |
Kamada | 149.55M |
Poseida Therapeutics | 82.50M |
Enanta Pharmaceuticals | 72.88M |
Cartesian Therapeutics | 25.91M |
XOMA Corporation | 5.81M |
Opthea | 385.28K |
ALIM News
- 6 hours ago - SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM - PRNewsWire
- 4 days ago - ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM - Business Wire
- 6 days ago - SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc. - Accesswire
- 8 days ago - Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher - Benzinga
- 8 days ago - Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders - PRNewsWire
- 8 days ago - ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals - GlobeNewsWire
- 8 days ago - Alimera Sciences stock rallies 75% on ANI Pharmaceuticals deal - Invezz
- 8 days ago - ALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to Shareholders - Business Wire